Multiple Myeloma: all 3,713 studies

Page 15 of 38. Open to participants first (754), then studies with results posted, then the rest; newest registration first within each.

• Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple MyelomaCompletedNCT00792142Phase 2Results posted
• Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney DysfunctionTerminatedNCT00790842Phase 1/2Results posted
• Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00790647Phase 2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerCompletedNCT00789776Phase 1/2Results posted
• Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological CancerCompletedNCT00787761Phase 2Results posted
• Study Combining Bortezomib With High Dose Melphalan to Treat Multiple MyelomaCompletedNCT00784823Phase 1/2Results posted
• Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)CompletedNCT00773838Phase 2Results posted
• Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)CompletedNCT00773747Phase 3Results posted
• Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00772915Phase 2Results posted
• Trial of Romidepsin and Bortezomib for Multiple MyelomaTerminatedNCT00765102Phase 2Results posted
• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure DisorderCompletedNCT00755040Phase 3Results posted
• Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)CompletedNCT00750815Phase 1/2Results posted
• A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple MyelomaCompletedNCT00747123Phase 2Results posted
• Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple MyelomaCompletedNCT00743288Phase 1/2Results posted
• A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple MyelomaCompletedNCT00742560Phase 2Results posted
• Bortezomib With Melphalan and Prednisone for Multiple MyelomaCompletedNCT00734149Phase 2Results posted
• Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)CompletedNCT00732641Phase 3Results posted
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
• Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple MyelomaCompletedNCT00724568Phase 1/2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerCompletedNCT00723099Phase 2Results posted
• A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple MyelomaCompletedNCT00722566Phase 3Results posted
• Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal FunctionCompletedNCT00721734Phase 2Results posted
• Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00719901Phase 1/2Results posted
• Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseCompletedNCT00719888Phase 2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other DiseaseTerminatedNCT00719849Phase 2Results posted
• American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3Results posted
• An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney FunctionTerminatedNCT00718640Phase 2Results posted
• A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple MyelomaCompletedNCT00718419Phase 2Results posted
• Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell MalignanciesTerminatedNCT00714259Phase 2/3Results posted
• Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCTCompletedNCT00709592Phase 2Results posted
• Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)CompletedNCT00701103Phase 1Results posted
• Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell TransplantationTerminatedNCT00698685Phase 2Results posted
• Study of MLN8237 in Participants With Advanced Hematological MalignanciesCompletedNCT00697346Phase 1Results posted
• Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance TherapyCompletedNCT00691704Phase 2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantCompletedNCT00691015Phase 2Results posted
• Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedNCT00689936Phase 3Results posted
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00687674Phase 1Results posted
• HD Melphalan and SCT in Patients With IGDD or LCDDTerminatedNCT00681044Phase 2Results posted
• Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00679367Phase 2Results posted
• A Phase II Study of Umbilical Cord Blood TransplantationTerminatedNCT00676806Phase 2Results posted
• Study of Natalizumab in Relapsed/Refractory Multiple MyelomaTerminatedNCT00675428Phase 1/2Results posted
• Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior TreatmentCompletedNCT00670631Phase 2Results posted
• Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3Results posted
• Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3Results posted
• Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma PatientsCompletedNCT00661544Phase 1/2Results posted
• Preemptive Strike With Bortezomib in Multiple Myeloma PatientsTerminatedNCT00657553Phase 3Results posted
• ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of PainCompletedNCT00656305Not applicableResults posted
• Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal FunctionCompletedNCT00652626Phase 1Results posted
• Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom BurdenCompletedNCT00651937Phase 2Results posted
• Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MMTerminatedNCT00648739Phase 1/2Results posted
• Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)CompletedNCT00642954Phase 1Results posted
• A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple MyelomaCompletedNCT00639002Phase 2Results posted
• Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple MyelomaCompletedNCT00635154Phase 2Results posted
• Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00635024Phase 2Results posted
• Clofarabine and Non-Myeloablative Allogeneic Hematopoietic TransplantationTerminatedNCT00626626Phase 1/2Results posted
• Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma ParticipantsCompletedNCT00622505Phase 4Results posted
• A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple MyelomaCompletedNCT00622336Phase 3Results posted
• A Study of Oral LBH589 in Adult Patients With Advanced Hematological MalignanciesCompletedNCT00621244Phase 1/2Results posted
• Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell TransplantCompletedNCT00619684Phase 2Results posted
• Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic CancersCompletedNCT00619645Phase 2Results posted
• Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)CompletedNCT00617591Phase 2Results posted
• Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning RegimenTerminatedNCT00615589Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT00612716Phase 2Results posted
• Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic CancerCompletedNCT00611351Phase 2Results posted
• Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00609167Phase 2Results posted
• An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)CompletedNCT00608907Phase 1Results posted
• Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate MofetilTerminatedNCT00608517Not applicableResults posted
• Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple MyelomaCompletedNCT00603447Phase 1Results posted
• Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00602641Phase 3Results posted
• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell TransplantTerminatedNCT00602446Phase 2Results posted
• Multi-day Doses in Prevention of Nausea and EmesisCompletedNCT00600353Phase 2Results posted
• In-Vivo Activated T-Cell Depletion to Prevent GVHDTerminatedNCT00594308Not applicableResults posted
• T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other DiseasesTerminatedNCT00589602Phase 2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerCompletedNCT00589563Phase 2Results posted
• Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple MyelomaCompletedNCT00581919Phase 2Results posted
• UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple MyelomaCompletedNCT00580372Phase 2Results posted
• Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)TerminatedNCT00579111Phase 1/2Results posted
• Bone Marker Assessment of Multiple Myeloma Patients Treated With AminobisphosphonatesCompletedNCT00577642Phase 2Results posted
• 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACECompletedNCT00577512Phase 2Results posted
• Effects of Exercise in Combination With Epoetin AlfaCompletedNCT00577096Not applicableResults posted
• Daratumumab (HuMax®-CD38) Safety Study in Multiple MyelomaCompletedNCT00574288Phase 2Results posted
• UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and ThalidomideTerminatedNCT00574080Phase 3Results posted
• Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2TerminatedNCT00573391Phase 3Results posted
• Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell TransplantCompletedNCT00571662Phase 2Results posted
• UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00569868Not applicableResults posted
• Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk LymphomaCompletedNCT00569309Not applicableResults posted
• Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple MyelomaTerminatedNCT00567229Phase 2Results posted
• Activated White Blood Cells With ASCT for Newly Diagnosed Multiple MyelomaCompletedNCT00566098Phase 1/2Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00564889Phase 2Results posted
• Dasatinib in Combination With Revlimid (and Dexamethasone)CompletedNCT00560391Phase 1Results posted
• Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple MyelomaTerminatedNCT00560352Phase 1Results posted
• CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or AmyloidosisCompletedNCT00558896Phase 2Results posted
• Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan RegimenCompletedNCT00556452Phase 1/2Results posted
• An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.CompletedNCT00555906Phase 2Results posted
• An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple MyelomaCompletedNCT00552396Phase 1Results posted
• Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart DysfunctionCompletedNCT00547365Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00540644Phase 2Results posted
• Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT00538824Phase 2Results posted
• Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple MyelomaCompletedNCT00538733Phase 2Results posted

← Multiple Myeloma overview